Trial Profile
A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Olodanrigan (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Acronyms EMPHENE
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Dec 2021 This trial has been completed in France (Global end date: 7 Mar 2019).
- 01 Oct 2021 Results of safety and efficacy data from two phase II studies (EMPHENE and EMPADINE) published in the Pain.
- 23 Mar 2020 This trial has been completed in Germany according to European Clinical Trials Database record.